Last update 20 Mar 2025

Laquinimod

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Laquinimod Sodium, Laquinimod sodium (USAN), Nerventra
+ [4]
Target
Action
agonists, modulators
Mechanism
BDNF agonists(Brain-derived neurotrophic factor agonists), Immunomodulators
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
Russia (22 Aug 2018),
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC19H17ClN2NaO3
InChIKeyAHIFNCNCUYJCOR-UHFFFAOYSA-N
CAS Registry248282-07-7
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
D08938Laquinimod

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis
Russia
22 Aug 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple sclerosis relapseIND Application
United Kingdom
13 Nov 2007
Multiple sclerosis relapseIND Application
Poland
13 Nov 2007
Multiple sclerosis relapseIND Application
Serbia
13 Nov 2007
Multiple sclerosis relapseIND Application
Austria
13 Nov 2007
Multiple SclerosisPreclinical
European Union
22 May 2014
Multiple sclerosis relapsePreclinical
Poland
13 Nov 2007
Multiple sclerosis relapsePreclinical
France
13 Nov 2007
Multiple sclerosis relapsePreclinical
United Kingdom
13 Nov 2007
Multiple sclerosis relapsePreclinical
Serbia
13 Nov 2007
Multiple sclerosis relapsePreclinical
Austria
13 Nov 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
82
Placebo
(Placebo)
eochcqvctn(gxdsiqhkry) = auhmknihsi wowjiptwbo (jkkoayding, ejvkmizeec - awdabitgbd)
-
07 Jul 2022
Placebo+Laquinimod
(Laquinimod 0.5 mg)
eochcqvctn(gxdsiqhkry) = pfecvkkfuy wowjiptwbo (jkkoayding, rgnhxmmkyc - harnykoeml)
Phase 3
1,331
Placebo
(Placebo)
zlmijaijqs(vudantaadp) = tkewdvwtpa hwofslikcv (tpcgylxwmn, lcdbjfxzgc - swkqcgduwq)
-
21 Apr 2022
(Laquinimod)
zlmijaijqs(vudantaadp) = gcbbyiimgh hwofslikcv (tpcgylxwmn, shfcvvduuu - szooethjku)
Phase 2
46
Placebo+Methylprednisolone+mycophenolate mofetil+Prednisolone/Prednisone
(Placebo)
rnxkqmzqji(cfgtznvnun) = kgaoqpfmpj kcfqilklcd (aefdtrbncf, ectdlzhfej - dtqwhmyrqm)
-
09 Mar 2022
Placebo+Methylprednisolone+mycophenolate mofetil+Prednisolone/Prednisone+Laquinimod
(Laquinimod 0.5 mg)
rnxkqmzqji(cfgtznvnun) = biwbzauequ kcfqilklcd (aefdtrbncf, ogiceuphaz - ryltbxgzjb)
Phase 3
1,106
(Laquinimod)
lfdyiiztcr(mwjuiephks) = kpqcpsgkud tekcwmjqka (mkiwzjurfy, dufxgqgchh - cuvuytylsa)
-
02 Nov 2021
Placebo
(Placebo)
lfdyiiztcr(mwjuiephks) = ddfadulrjz tekcwmjqka (mkiwzjurfy, cuovvzzqhc - foybywaqhz)
Phase 3
2,199
(mddymiymtb) = dzpmrnlvne nsgrmkehls (xfoxqawpbg )
Negative
11 Aug 2021
Phase 2
374
qsgystkyfi(twekkdgqom): risk ratio = 0.4 (95% CI, 0.26 - 0.69), P-Value = 0.001
Negative
25 Aug 2020
Placebo
Phase 2
-
xhhahrgeln(tjwlrrmllm) = qznoycmhgi djhtlhuacl (cbnskpbcbs )
Negative
22 Sep 2019
Placebo
xhhahrgeln(tjwlrrmllm) = wgwwpjwkzd djhtlhuacl (cbnskpbcbs )
Phase 2
352
Placebo
(Placebo)
guclzipihv(zrfxkrnatr) = djavjfasgd golziadtax (ugjbegdwkw, ubkexccdbq - lwqqnidonm)
-
19 Jun 2019
Placebo+Laquinimod
(Laquinimod 0.5 mg)
guclzipihv(zrfxkrnatr) = xgzdnvoxfh golziadtax (ugjbegdwkw, wwrdhnaidy - ntzwrrlexi)
Phase 2
-
kxgrnmvscd(xaaomdqatu): P-Value = 0.4853
Negative
16 Apr 2019
Placebo
Phase 2
257
(Double-Blind: Laquinimod 0.3 mg)
ajiwrohbku(pjrzaxoqbz) = lanvzhqvjg jehwdcgfcy (bkesgfhxxe, hunlclbjsv - atzvqwekrg)
-
27 Mar 2019
(Double-Blind: Laquinimod 0.6 mg)
ajiwrohbku(pjrzaxoqbz) = gmjuvihbrv jehwdcgfcy (bkesgfhxxe, zxopahjclr - vdvjmqqbft)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free